An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

Lepodisiran, a new drug, slashed levels of “stealthy cholesterol”—a hidden heart risk affecting 1 in 5 people—by up to 95% in ...

Researchers have discovered an experimental medication that significantly reduces a cholesterol-like particle that can ...

WEDNESDAY, April 9, 2025 (HealthDay News) -- An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

A poll conducted in April and May of 2024 found that around 12 percent of Americans have tried a GLP-1 drug such as Ozempic, Wegovy, Zepbound, or Mounjaro—a number that has likely only grown ...

In 2024, the FDA's Center for Drug Evaluation and Research (CDER) approved 50 new drugs. The CDER director, Patrizia ...

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Reviews of the latest movies starring Henry Golding and Peter Sarsgaard. Read more at straitstimes.com. Read more at ...

The FDA laid out a three-year roadmap to phase out animal toxicity testing in drug research. In addition to organoids and lab ...

That amounted to a 31% reduction of disability with the experimental drug. Tolebrutinib also demonstrated other positive benefits, results show: Nearly twice as many patients taking the drug ...